Transthyretin Amyloidosis Treatment Market Top Companies Study - American Express, Bank of America Corporation, Barclays PLC, Capital One, Citigroup Inc., JPMorgan Chase & Co.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Transthyretin Amyloidosis Treatment Market - (By Type (ATTR-PN, ATTR-CM), By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy), By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Transthyretin Amyloidosis Treatment Market is valued at US$ 5.2 billion in 2023, and it is expected to reach US$ 9.4 billion by 2031, with a CAGR of 7.90% during the forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2890

Transthyretin amyloidosis (ATTR) treatment encompasses therapeutic interventions aimed at managing and slowing the progression of this rare, progressive, and potentially life-threatening disorder caused by the accumulation of misfolded transthyretin protein in various tissues and organs. Current treatment approaches include pharmacological therapies designed to stabilize the transthyretin protein or reduce its production, as well as supportive care to alleviate symptoms and manage associated complications.

The transthyretin amyloidosis treatment market is expected to experience robust growth due to increasing awareness and improved diagnostic capabilities for rare diseases. The condition's frequent underdiagnosis among individuals with chronic illnesses presents a significant opportunity for earlier identification and intervention. This, coupled with a rise in the availability of advanced diagnostic tools, is anticipated to expand the treatable patient population.

Furthermore, an uptick in clinical research focused on developing pipeline therapies for ATTR amyloidosis and related disorders is contributing to market momentum. Government-led initiatives aimed at raising public and healthcare provider awareness-combined with enhanced reimbursement policies-are also playing a pivotal role in promoting treatment adoption and fostering market growth on a global scale.

List of Prominent Players in the Transthyretin Amyloidosis Treatment Market:
• Acrotech Biopharma, LLC
• Alnylam Pharmaceuticals, Inc.
• AstraZeneca PLC
• Astellas Pharma Inc.
• BridgeBio Pharma, Inc.
• Bristol-Myers Squibb Company
• Ionis Pharmaceuticals, Inc.
• Johnson & Johnson
• Prothena Biosciences Limited
• Pfizer Inc.
• SOM Innovation Biotech, S.L.
• Abbvie, Inc.
• Sanofi
• Eidos Therapeutics, Inc
• BELLUS Health Inc

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-03

Market Dynamics
Drivers:
The global transthyretin amyloidosis treatment market is witnessing increasing demand, primarily driven by the rapid expansion of the elderly population, which is projected to grow by 16% and reach approximately 1.5 billion individuals in the coming years. This demographic trend is closely associated with a rising incidence of transthyretin amyloidosis, particularly among geriatric patients. According to data from Prothena, over 400,000 individuals globally are affected by wild-type ATTR (ATTRwt) amyloidosis, while approximately 50,000 individuals have hereditary ATTR (hATTR) amyloidosis. The National Center for Biotechnology Information (NCBI) highlights that ATTRwt predominantly affects the heart and is strongly correlated with advancing age, positioning aging as a significant risk factor. To enhance awareness, initiatives such as the biennial touring workshop organized by the Australian Amyloidosis Network have been instrumental in educating healthcare professionals and patients about ATTR amyloidosis and available treatment options.

Challenges:
Despite growing awareness, the market faces notable challenges. One key barrier is the lack of adequate knowledge among healthcare providers, which can result in delayed or incorrect diagnoses and inappropriate treatment regimens. Furthermore, the high cost of novel therapies poses a significant constraint to widespread adoption. For example, Alnylam Pharmaceuticals reports that the annual cost of Patisiran, a newly approved treatment, is approximately USD 450,000. Similarly, Inotersen, another approved therapy, is priced at a comparable level, which may limit accessibility for a broader patient population.

Regional Trends:
North America is expected to hold a leading share in the transthyretin amyloidosis treatment market, supported by increasing prescription rates, improved diagnosis, and growing treatment uptake. The approval of ONPATTRO (Patisiran) by Health Canada for the treatment of hATTR polyneuropathy has notably contributed to regional market growth. Meanwhile, the Middle East and Africa are also emerging as key markets due to high unmet medical needs, increasing disease prevalence, and a rising number of drug approvals. These regions benefit from a large patient population, ongoing healthcare reforms, and enhanced disease awareness, all of which are expected to drive significant market expansion in the foreseeable future.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2890

Segmentation of Transthyretin Amyloidosis Treatment Market-
By Type-
• ATTR-PN
• ATTR-CM
By Therapy-
• Targeted Therapy
o Onpattro
o Inotersen
o Vyndaqel/Vyndamax
• Supportive Therapy
• Pipeline Therapy
By Disease Type-
• Hereditary Transthyretin Amyloidosis
o Polyneuropathy
o Cardiomyopathy
o Mixed Type
• Wild Type Amyloidosis
By Distribution Channel-
• Hospital Pharmacies
• Specialty Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/transthyretin-amyloidosis-treatment-market/2890

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.